Psychiatry Investig.
2010 Sep;7(3):189-195.
Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
- Affiliations
-
- 1Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. cykim@amc.seoul.kr
- 2Department of Psychiatry, Seoul National Hospital, Seoul, Korea.
- 3Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea.
- 4Department of Psychiatry, Hallym University College of Medicine, Chuncheon, Korea.
- 5Department of Psychiatry, College of Medicine, Inha University, Incheon, Korea.
- 6Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 7Department of Psychiatry, Our Lady of Mercy Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
- 8Department of Psychiatry, Korea University College of Medicine, Seoul, Korea.
- 9Department of Psychiatry, College of Medicine, Dankook University, Cheonan, Korea.
- 10Yong-In Mental Hospital, Yongin, Korea.
Abstract
OBJECTIVE
To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks).
METHODS
This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study.
RESULTS
At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea.
CONCLUSION
This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Study for Switching Strategies from Previous Antipsychotics to Aripiprazole: A One-Year Naturalistic Study
- Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
- Worsening of Psychotic Symptoms in Patients with Chronic Schizophrenia after Switching to or Combining Aripiprazole and Aripiprazole Monthly (Abilify Maintena)
- Strategies for Switching Antipsychotics
- Comparison of Aripiprazole and Other Atypical Antipsychotics for Pediatric Bipolar Disorder: A Retrospective Chart Review of Efficacy and Tolerability
